Cargando…

Should a Multigene Signature be Used in all Luminal Early Breast Cancers

Background: Multigene signatures refine the risk of recurrence and guide adjuvant chemotherapy decision in luminal breast cancers. The decision to perform the assay is highly variable among oncologists. In order to guide the appropriate clinical group in whom to perform a genomic signature, our stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hajjaji, Nawale, Robin, Yves Marie, Bonneterre, Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558017/ https://www.ncbi.nlm.nih.gov/pubmed/31214499 http://dx.doi.org/10.3389/fonc.2019.00454

Ejemplares similares

Path to Clonal Theranostics in Luminal Breast Cancers
por: Hajjaji, Nawale, et al.
Publicado: (2022)

Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group
por: Licata, Luca, et al.
Publicado: (2023)

PROCURE European consensus on breast cancer multigene signatures in early breast cancer management
por: Curigliano, Giuseppe, et al.
Publicado: (2023)

Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology
por: Valentini, Virginia, et al.
Publicado: (2023)

16 Months Follow Up of Patients’ Behavior and Mild COVID-19 Patterns in a Large Cohort of Cancer Patients During the Pandemic
por: Hajjaji, Nawale, et al.
Publicado: (2022)

Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer
por: Ovcaricek, Tanja, et al.
Publicado: (2019)

Comprehensive proteome, phosphoproteome and kinome characterization of luminal A breast cancer
por: Yang, Ganglong, et al.
Publicado: (2023)

Development and validation of an ultrasound-based radiomics nomogram for predicting the luminal from non-luminal type in patients with breast carcinoma
por: Wu, Jiangfeng, et al.
Publicado: (2022)

A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer
por: Sun, Li, et al.
Publicado: (2019)

SIRT7 Is a Prognostic Biomarker Associated With Immune Infiltration in Luminal Breast Cancer
por: Huo, Qin, et al.
Publicado: (2020)

RNA m(6)A Methylation Regulators Subclassify Luminal Subtype in Breast Cancer
por: Yang, Lin, et al.
Publicado: (2021)

Implementation of multigene panel testing for breast and ovarian cancer in South Africa: A step towards excellence in oncology for the public sector
por: van der Merwe, Nerina C., et al.
Publicado: (2022)

Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
por: Diana, Anna, et al.
Publicado: (2022)

Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
por: Hao, Junmei, et al.
Publicado: (2021)

Identification of Luminal A breast cancer by using deep learning analysis based on multi-modal images
por: Liu, Menghan, et al.
Publicado: (2023)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer
por: Exner, R, et al.
Publicado: (2014)

Quantitative Multigene FISH on Breast Carcinomas Identifies der(1;16)(q10;p10) as an Early Event in Luminal A Tumors
por: Rye, Inga H, et al.
Publicado: (2015)

Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management
por: Slavin, Thomas Paul, et al.
Publicado: (2015)

Corrigendum: Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management
por: Slavin, Thomas Paul, et al.
Publicado: (2015)

Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer
por: Belardinilli, Francesca, et al.
Publicado: (2020)

Identification of prognostic cancer-associated fibroblast markers in luminal breast cancer using weighted gene co-expression network analysis
por: Xu, An, et al.
Publicado: (2023)

ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer
por: Gong, Yajie, et al.
Publicado: (2020)

Extracellular Vesicles Induce an Aggressive Phenotype in Luminal Breast Cancer Cells Via PKM2 Phosphorylation
por: Kang, Seo Young, et al.
Publicado: (2021)

Investigating a multigene prognostic assay based on significant pathways for Luminal A breast cancer through gene expression profile analysis
por: Gao, Haiyan, et al.
Publicado: (2018)

Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2022)

Spontaneous Osteoclastogenesis, a risk factor for bone metastasis in advanced luminal A-type breast cancer patients
por: Fernández Vallone, Valeria, et al.
Publicado: (2023)

High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study
por: Jääskeläinen, Anniina, et al.
Publicado: (2020)

Application of DCE-MRI radiomics signature analysis in differentiating molecular subtypes of luminal and non-luminal breast cancer
por: Huang, Ting, et al.
Publicado: (2023)

Vitamin D Deficiency is Correlated with Poor Outcomes in Patients with Luminal-type Breast Cancer
por: Kim, Hee Jeong, et al.
Publicado: (2010)

First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer
por: Ettl, Johannes, et al.
Publicado: (2020)

Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis
por: Curtit, Elsa, et al.
Publicado: (2023)

Multigene tests for breast cancer: the physician’s perspective
por: Cognetti, Francesco, et al.
Publicado: (2021)

Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients: FN14 and GRP94 from Diagnosis to Prophylaxis
por: Martínez-Aranda, Antonio, et al.
Publicado: (2017)

Dysregulation of TLR2 Serves as a Prognostic Biomarker in Breast Cancer and Predicts Resistance to Endocrine Therapy in the Luminal B Subtype
por: Wang, Yunmei, et al.
Publicado: (2020)

Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and C-Reactive Protein/Albumin Ratio in Luminal Breast Cancers With HER2-Negativity
por: Chen, Fei, et al.
Publicado: (2022)

Androgens in Patients With Luminal B and HER2 Breast Cancer Might Be a Biomarker Promoting Anti-PD-1 Efficacy
por: Li, Peng, et al.
Publicado: (2022)

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature
por: Albarrán, Víctor, et al.
Publicado: (2023)

Fallopian tube lesions as potential precursors of early ovarian cancer: a comprehensive proteomic analysis
por: Wisztorski, Maxence, et al.
Publicado: (2023)

Somatic mutations in early onset luminal breast cancer
por: Encinas, Giselly, et al.
Publicado: (2018)

Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report
por: Allegretti, Matteo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fjslh9hsegn0plvgticdua0fjj